Funded Startups in Alameda
Among the 30 most recent funded entries for Alameda (sorted by round date descending), the largest disclosed round is Sila Nanotechnologies at $100M (2026-…
Among the 30 most recent funded entries for Alameda (sorted by round date descending), the largest disclosed round is Sila Nanotechnologies at $100M (2026-04-08). That amount sits far above the next-largest disclosed numbers in this window, including Science at $230M (2026-03-05) and Science again at $104M (2025-04-14); in other words, the disclosed amounts are highly uneven, with a handful of very large biotech rounds framing much smaller checks. The list also shows clustering in time: multiple rounds fall in spring 2026 (e.g., Science $230M on 2026-03-05, Sila $100M on 2026-04-08, Paloma Learning $9M on 2026-06-03, and Scribe Therapeutics $25M on 2026-06-18). Sector-wise, Biotechnology is the most repeated category, appearing at Scribe Therapeutics (2026-06-18), Science (2026-03-05 and 2025-04-14), iMicrobes (2024-11-19), MIIST Therapeutics (2025-02-05), Santa Ana Bio (2024-06-13), AgeX Therapeutics (2023-07-21), Checkerspot (2023-02-14), and others, indicating biotech dominance in Alameda. Stage naming is mixed: 17 of 30 rows use “Series Unknown”, and 1 row is explicitly “undisclosed” (Terviva, 2025-08-04), while dates span from 2022-06-03 (Kairos Power) through 2026-06-18 (Scribe Therapeutics).
Most recent rounds
30 shownRelated listings
Frequently asked
What’s the largest disclosed funding amount in this Alameda set, and how skewed are the disclosed amounts around it?
The largest disclosed amount is Science at $230M on 2026-03-05 (Biotechnology), with the next-largest disclosed amounts including Sila Nanotechnologies at $100M on 2026-04-08 and Science at $104M on 2025-04-14. Aside from these few large biotech/health-linked rounds, many other disclosed entries sit in the tens of millions or below (for example, Paloma Learning $9M on 2026-06-03 and Alveo Technologies $200K on 2026-05-26).
Are there notable time clusters among the most recent rounds?
Yes. Spring 2026 contains multiple high-visibility closes: Science $230M (2026-03-05), Sila Nanotechnologies $100M (2026-04-08), Alveo Technologies $200K (2026-05-26), Paloma Learning $9M (2026-06-03), and Scribe Therapeutics $25M (2026-06-18). The dataset also starts tight at the top end, with the most recent date being 2026-06-18 (Scribe Therapeutics).
Which sectors show over-representation in Alameda among these 30 entries?
Biotechnology is the clearest concentration, appearing repeatedly across rows such as Science (2026-03-05; $230M), Scribe Therapeutics (2026-06-18; $25M), Santa Ana Bio (2024-06-13; $125M), iMicrobes (2024-11-19; $10M), AgeX Therapeutics (2023-07-21; $36M), and Checkerspot (2023-02-14; $55M). Other sectors appear, but none match the frequency pattern of Biotechnology in the rows shown.
What does the stage naming suggest—does “Series Unknown” dominate?
Stage labels are difficult to compare because “Series Unknown” appears in 17 of 30 rows (for example, Scribe Therapeutics on 2026-06-18; Paloma Learning on 2026-06-03; and Saildrone on 2025-05-13). By contrast, labeled stages like Seed (MIIST Therapeutics 2025-02-05 at $7M; Mimosa Therapeutics 2021-02-10 at $900K) and Series C (Science 2026-03-05 at $230M; Checkerspot 2023-02-14 at $55M) show up less often in this top-30 slice.
Are there outliers worth flagging, either by disclosed amount or amount disclosure status?
The smallest disclosed amount is $20K for Kairos Power (Grant) on 2022-06-03, which is far below most other disclosed rounds in the table. Separately, Terviva (Agriculture and Farming) on 2025-08-04 is explicitly “undisclosed,” so it doesn’t participate in disclosed-size comparisons; nearby disclosed checks around it include Natel Energy $15M (2025-07-29) and Saildrone $60M (2025-05-13).
What’s the range of round dates covered by the rows shown, and which entries define the temporal edges?
The listed rounds span from 2022-06-03 (Kairos Power; Grant; $20K) up to 2026-06-18 (Scribe Therapeutics; Series Unknown; $25M). That creates a multi-year view where the most recent edge is defined by biotech/health-linked companies (Scribe Therapeutics) while the oldest edge is an energy grant (Kairos Power).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.